Jay Srinivasan

🚀 Commercial Blitz Ranks Sarcomatrix “Highly Fundable” We’re proud to share that Sarcomatrix Therapeutics has been scored as highly fundable in the latest CommerceBlitz Capital Readiness Report. 📊 Capital Readiness Scores Product/Service: 8.5 – Differentiated oral small molecule targeting α7β1 integrin with strong early data. Traction: 7.5 – $8M+ NIH funding, 75+ patents pending, global conference selections. Market: 8.8 – Expanding orphan and aging-related muscle disease markets with strong regulatory incentives. Finance: 7.2 – Prudent burn and credible forecasts; focused on closing the $5M Seed+ round. Founder: 9.5 – David Craig brings 30+ years of proven biopharma leadership (Amgen, Gilead, Alexion). Founding Team: 8.0 – Deep regulatory and translational expertise, scaling commercial capacity. Differentiation: 9.0 – First-in-class potential with broad IP protection. Performance Quality: 8.6 – Strong progress for pre-IND stage, positioned for acceleration with Phase I data. Success Likelihood: 8.0 – High alignment of science, IP, and regulatory strategy with moderate capital-driven execution risk. 🔎 Interpretation Sarcomatrix stands out for its market potential, differentiated product strategy, and leadership strength. While earlier-stage than many peers on immediate traction, our progress places us firmly in the highly fundable category with significant upside. With IND-enabling milestones underway and Phase I trials on the horizon, Sarcomatrix is poised to strengthen its position across every dimension of the Capital Readiness framework.

28

2 Comments

Home testing with Labcorp is transforming healthcare by making vital lab services accessible to everyone, right from the comfort of their homes. Innovative at-home testing solutions empower individuals to take control of their health, reducing barriers to essential diagnostics and streamlining the path from testing to treatment.​ Benefits of Labcorp Home Testing At-home lab testing increases convenience and privacy, allowing tests to be completed on your schedule without needing to visit a clinic.​ It supports early detection and ongoing health monitoring for a wide range of conditions, from wellness panels to specialty diagnostics.​ Labcorp’s commitment to innovation continues to expand access and ensure reliable, high-quality results for individuals and families everywhere.​ Expanding access through home testing means a healthier, more connected community—where healthcare fits every lifestyle. #Labcorp #AtHomeTesting #HealthcareInnovation #AccessToCare #WellnessFromHome #DiagnosticTesting #LabcorpOnDemand #TakeControl #ConvenientCare #HomeLabTests #PatientCentered #HealthEquity #PreventiveHealth #RemoteDiagnostics #HealthAtHome

7

A turning point for precision medicine: FDA just proposed moving companion diagnostics from Class III to Class II. So diagnostic tests that previously required full PMA would now clear through 510(k), provided they meet special controls. Why this matters:👇 1. Diagnostics development suffered by PMA timelines and cost. Time to market was so long that investor interest is nearly zero for this entire category. A 510(k) significantly shortens time to market and cost, removing a major structural bottleneck. 2. Oncology now depends on molecular stratification. Faster CDx clearance tightens the therapeutic diagnostic loop and reduces latency between biomarker discovery and clinical deployment. 3. Market Shifts: Lowering the regulatory barrier for diagnostics changes the economics of precision oncology. More assays get built. More subpopulations get identified. More therapeutics can be matched to a precise patient profile instead of broad labels. If finalized, this will materially change targeted drug development. We do need more diagnostics, and the barrier just got lower. It’s a great time to build. If you’re working in this space, send me a DM. Hashtags: #oncology #precisionmedicine #regulation #diagnostics #FDA Credit Image: 360Dx, article link in comments

141

9 Comments